• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Ribociclib Aids First-Line Endocrine Therapy in Premenopausal Advanced Breast Cancer

  • in AJO · Audio · Oncology
  • — 18 Apr, 2018
Ribociclib Aids First-Line Endocrine Therapy in Premenopausal Advanced Breast Cancer
Nadia Harbeck talks about ribociclib in premenopausal breast cancer
Ribociclib Aids First-Line Endocrine Therapy in Premenopausal Advanced Breast Cancer
AudioMedica News
Ribociclib Aids First-Line Endocrine Therapy in Premenopausal Advanced Breast Cancer
Ribociclib Aids First-Line Endocrine Therapy in Premenopausal Advanced Breast Cancer
00:00 / 8:00
Apple Podcasts Spotify Stitcher
RSS Feed
Share
Link
Embed
//-->//>' class="input-embed input-embed-3570"/>

Subscribe: Apple Podcasts | Spotify | Stitcher

BARCELONA—More pre-menopausal women who have estrogen receptor (ER) positive advanced breast cancer could be spared chemotherapy—according to latest findings from the MONALEESA-7 double-blind randomized phase 3 trial in which either placebo (PBO) or the cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib (RIB) were added to tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with all patients also having ovarian suppression by goserelin therapy.

https://www.ecco-org.eu/Events/EBCC11/Searchable-Programme#anchorScpr

At the 2018 European Breast Cancer Conference (EBCC 11) Nadia Harbeck MD, Professor of Gynaecology and head of the Breast Center at the University of Munich in Germany said that following her group’s latest study findings practice should change for young, pre-menopausal patients who presented for the first time with hormone receptor positive human epidermal growth factor receptor2- (HER2)-negative advanced breast cancer. She discusses her findings with the Audio Journal of Oncology.

Emiel J T Rutgers MD PhD FRCS from the Netherlands Cancer Institute, Professor of Surgical Oncolology at the University of Amsterdam, who was not involved with the study, said the results were very interesting. “We have now another possibility added to our armamentarium. My opinion is that in pre-menopausal women who recur with hormone-sensitive estrogen-dependent breast cancer with visceral or bony metastasis a re-challenge with anti-hormonal treatment including ribociclib or a comparable [agent] is now the first option. And the side-effect profile is rather mild—so that’s another positive thing about it.”

LATE BREAKING ABSTRACT 1LBA:

Ribociclib (RIB) plus tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): additional results from the MONALEESA-7 trial

https://www.ecco-org.eu/Events/EBCC11/Searchable-Programme#anchorScpr

 

 

You may also like...

  • Daniel W. Lee Chimeric antigen receptor T-cell therapy rescues kids with relapsing acute lymphoblastic leukaemia 6 Aug, 2013
  • Audio Journal of Oncology in Advance – March 15th, 2008 Audio Journal of Oncology in Advance – March 15th, 2008 16 Mar, 2008
  • Orteronel shows no survival advantage in metastatic castration-resistant prostate cancer: phase III randomized study finds Orteronel shows no survival advantage in metastatic castration-resistant prostate cancer: phase III randomized study finds 6 Feb, 2014
  • Andrew Loblaw Low risk localized prostate cancer: no harm from waiting! 24 Mar, 2013

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story Reassurance on Ductal Carcinoma in Situ (DCIS) Treatment De-Escalation
  • Next story Breast Lumps Between Mammography Visits Signal High Risk
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic…
    • Microbiome Diversity Key To Survival After…
    • New Front Line Standard for Older Patients with…
    • Palbociclib Combination Prolongs Life After Breast…
    • Breast Lumps Between Mammography Visits Signal High Risk
  • Home
  • Oncology
  • AJO
  • Ribociclib Aids First-Line Endocrine Therapy in Premenopausal Advanced Breast Cancer

© COPYRIGHT 2020 AUDIOMEDICA.COM.